Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPT NASDAQ:INMD NASDAQ:MDXG NASDAQ:PLSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$10.57-3.5%$11.01$9.76▼$19.22$300.33M0.89313,327 shs238,172 shsINMDInMode$14.98-0.6%$14.54$13.14▼$19.85$946.57M21.26 million shs987,963 shsMDXGMiMedx Group$6.90-3.1%$6.93$5.47▼$10.14$1.02B1.74668,088 shs360,557 shsPLSEPulse Biosciences$14.75-1.2%$15.50$13.77▼$25.00$992.94M1.68170,561 shs293,430 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+0.18%+4.99%+1.20%-14.79%-7.52%INMDInMode-1.37%+4.58%+6.80%+5.53%-2.90%MDXGMiMedx Group-0.70%-0.97%+1.42%+10.90%+15.77%PLSEPulse Biosciences-0.66%-1.13%+1.56%-10.70%-14.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$10.57-3.5%$11.01$9.76▼$19.22$300.33M0.89313,327 shs238,172 shsINMDInMode$14.98-0.6%$14.54$13.14▼$19.85$946.57M21.26 million shs987,963 shsMDXGMiMedx Group$6.90-3.1%$6.93$5.47▼$10.14$1.02B1.74668,088 shs360,557 shsPLSEPulse Biosciences$14.75-1.2%$15.50$13.77▼$25.00$992.94M1.68170,561 shs293,430 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+0.18%+4.99%+1.20%-14.79%-7.52%INMDInMode-1.37%+4.58%+6.80%+5.53%-2.90%MDXGMiMedx Group-0.70%-0.97%+1.42%+10.90%+15.77%PLSEPulse Biosciences-0.66%-1.13%+1.56%-10.70%-14.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$19.6786.15% UpsideINMDInMode 2.13Hold$18.0420.48% UpsideMDXGMiMedx Group 3.00Buy$12.0073.94% UpsidePLSEPulse Biosciences 3.00Buy$22.0049.11% UpsideCurrent Analyst Ratings BreakdownLatest CLPT, MDXG, PLSE, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.007/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$11.00 ➝ $12.007/30/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $21.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$11.007/11/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$15.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$22.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$33.59M8.94N/AN/A$0.92 per share11.48INMDInMode$394.82M2.40$1.79 per share8.38$10.12 per share1.48MDXGMiMedx Group$363.77M2.81$0.32 per share21.64$1.31 per share5.27PLSEPulse Biosciences$700K1,418.49N/AN/A$1.87 per share7.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)INMDInMode$181.27M$2.476.068.23N/A44.50%18.38%16.35%10/29/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2132.8521.56N/A8.84%23.03%17.09%10/29/2025 (Estimated)PLSEPulse Biosciences-$53.58M-$1.05N/A∞N/AN/A-63.19%-54.98%10/29/2025 (Estimated)Latest CLPT, MDXG, PLSE, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/12/2025Q2 2025PLSEPulse Biosciences-$0.26-$0.28-$0.02-$0.28$0.50 millionN/A7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint Neuro1.467.306.45INMDInModeN/A9.608.58MDXGMiMedx Group0.084.393.90PLSEPulse BiosciencesN/A12.0512.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%INMDInMode68.04%MDXGMiMedx Group79.15%PLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.97%INMDInMode6.92%MDXGMiMedx Group1.70%PLSEPulse Biosciences74.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11028.43 million26.69 millionOptionableINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionablePLSEPulse Biosciences14067.30 million17.09 millionOptionableCLPT, MDXG, PLSE, and INMD HeadlinesRecent News About These CompaniesPulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting1 hour ago | finance.yahoo.comPulse Biosciences Gains FDA Approval for NANOCLAMP StudySeptember 9 at 10:58 AM | msn.comPulse Biosciences granted FDA approval for investigational device exemptionSeptember 8 at 11:54 AM | msn.comPulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial FibrillationSeptember 8 at 11:54 AM | finance.yahoo.comPulse Biosciences wins FDA IDE to conduct study of PFA tech for AFibSeptember 8 at 11:54 AM | massdevice.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comNuveen LLC Invests $915,000 in Pulse Biosciences, Inc $PLSESeptember 4, 2025 | marketbeat.comPulse Biosciences Announces Success in Thyroid StudySeptember 3, 2025 | msn.comPulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) StudySeptember 2, 2025 | joplinglobe.comJPLSE Shares Rise on First-in-Human Data for Thyroid Nodule TreatmentAugust 27, 2025 | zacks.comPulse Biosciences reports first-in-human data for PFA to treat benign thyroid nodulesAugust 27, 2025 | massdevice.comPulse Biosciences (NASDAQ:PLSE) Trading Down 5.2% - Time to Sell?August 17, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Trading Up 7.1% - What's Next?August 15, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Releases Earnings ResultsAugust 14, 2025 | marketbeat.comPulse Biosciences Reports Q2 2025 Progress and ResultsAugust 13, 2025 | msn.comPulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comPulse Biosciences Reports Business Updates and Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comPandora Wealth Inc. Takes Position in Pulse Biosciences, Inc (NASDAQ:PLSE)August 10, 2025 | marketbeat.comPulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth ConferenceAugust 1, 2025 | finance.yahoo.comPulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025July 29, 2025 | businesswire.comOppenheimer Initiates Coverage of Pulse Biosciences (PLSE) with Outperform RecommendationJuly 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLPT, MDXG, PLSE, and INMD Company DescriptionsClearPoint Neuro NASDAQ:CLPT$10.56 -0.39 (-3.52%) Closing price 03:59 PM EasternExtended Trading$10.53 -0.04 (-0.33%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.InMode NASDAQ:INMD$14.98 -0.10 (-0.63%) Closing price 03:59 PM EasternExtended Trading$15.03 +0.05 (+0.37%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$6.90 -0.22 (-3.10%) Closing price 03:59 PM EasternExtended Trading$6.88 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Pulse Biosciences NASDAQ:PLSE$14.75 -0.19 (-1.24%) Closing price 03:59 PM EasternExtended Trading$14.80 +0.05 (+0.31%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
